Relationship Between Ku80 Protein Content and Sensitivity to Cisplatin of HumanLung Cancer Cells_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

REN Zhenyi , YE Sheng , YE Jian , WANG Limin.

Department of Respiratory Medicine, First Hospital of Hangzhou. Hangzhou, Zhejiang, 310006, ChinaCorresponding Author: REN Zhen-yi, E-mail: huxike123@ yahoo. com. cn;

Corresponding author：

Keywords：

Ku80; Lung cancer; Cisplatin; Half maximal inhibitory concentration

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective Non-small cell lung cancer ( NSCLC) cells are relatively resistant to chemotherapy, and the outcomes are not always satisfactory. This study was designed to explore the relationship between the content of Ku80 protein of human lung cancer cells and their sensitivity to cisplatin.Methods The lung cancer cells isolated frommalignant pleural effusion samples frompatients with primary lung cancer were cultured in vitro. The sensitivity to cisplatin was tested with the method of CCK-8 expressed as half maximal inhibitory concentration ( IC50 ) . The relative content of Ku80 protein was determined by Western blot. The correlation between sensitivity to cisplatin of lung cancer cells and the relative content of Ku80 protein was analyzed. Results The IC50 of NSCLC group was significantly higher than that of SCLC
group [ ( 4. 40 ±3. 39) mg/L vs. ( 1. 02 ±0. 54) mg/L, P lt; 0. 001] . The relative content of Ku80 protein of NSCLC group was statistically higher than that of SCLC group [ ( 0. 80 ±0. 45) vs. ( 0. 48 ±0. 25) , P lt;0. 05] . The correlation coefficient between content of Ku80 protein and IC50 was 0. 618 ( P lt; 0. 001) .Conclusions The content of Ku80 protein of NSCLC patients is higher than that of SCLC patients. Itmay be one of the mechanisms contributing to chemotherapeutic resistance of NSCLC. There is a negative relationship between Ku80 protein content of cancer cells and their sensitivity to cisplatin suggesting that the content of Ku80 protein may be served as a candidate index for predicting sensitivity of lung cancer cells to cisplatin.

Citation： REN Zhenyi,YE Sheng,YE Jian,WANG Limin.. Relationship Between Ku80 Protein Content and Sensitivity to Cisplatin of HumanLung Cancer Cells. Chinese Journal of Respiratory and Critical Care Medicine, 2010, 9(6): 631-634. doi: Copy

1.	Cho BC, Kim JH, Soo RA, et al. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J, 2010, 51: 1-8 .
2.	Yang CT, Hung JY, Lai CL, et al. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan. Kaohsiung J Med Sci, 2010, 26: 1-7.
3.	Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 2010, 35: 202 -215.
4.	Shao CJ, Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol, 2008 , 89: 27-35.
5.	任振义, 金一尊. Ku 蛋白在肿瘤发生中的作用及其靶向抑制策略. 国际放射医学核医学杂志, 2008, 32: 305-307.
6.	Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer, 2002, 95: 1199-1205.
7.	Tseng RC, Hsieh FJ, Shih CM, et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous endjoining pathway genes: a multiple genotype-phenotype study.Cancer, 2009 , 115: 2939-2948.
8.	Kuribayashi T, Ohara M, Sora S, et al. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med, 2010, 25: 25-29.
9.	熊建文, 肖化, 张镇西. MTT 法和CCK-8 法检测细胞活性之测试条件比较. 激光生物学报, 2007, 16: 559 -562.
10.	唐梦琳, 邓万明. 肺癌顺铂耐药的分子机制研究进展. 华西医学, 2009, 24: 238-240 .
11.	方美玉. 进展期非小细胞肺癌治疗进展. 中国呼吸与危重监护杂志, 2008 , 7: 481-484 .
12.	金儿, 任振义, 卢忠, 等. X 线照射后A549 肺癌细胞Ku80 mRNA 及其蛋白表达的变化. 中华放射医学与防护杂志, 2009, 29: 393 -395.
13.	Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNAPKcs reveals a large open-ring cradle comprised of HEAT repeats.Nature, 2010, 463 : 118-121.
14.	Deriano L, Stracker TH, Baker A, et al. Roles for NBS1 in alternative nonhomologous end-joining of V ( D) J recombination intermediates.Mol Cell, 2009, 34 : 13-25.
15.	韩国栋, 王远东, 袁进, 等. 体外肿瘤药敏试验指导非小细胞肺癌个体户新辅助化疗的临床研究. 内科, 2008 , 3: 493-496 .
16.	Xing J, Wu X, Vaporciyan AA, et al. Prognostic significance of ataxia- telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with non-small cell lung cancer.Cancer, 2008 , 112: 2756-2764.
17.	Liu B, Wang T, Qian X, et al. Anticancer effect of tetrandrine on primary cancer cells isolated fromascites and pleural fluids. Cancer Lett, 2008, 268: 166-175.

1. Cho BC, Kim JH, Soo RA, et al. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J, 2010, 51: 1-8 .
2. Yang CT, Hung JY, Lai CL, et al. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan. Kaohsiung J Med Sci, 2010, 26: 1-7.
3. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 2010, 35: 202 -215.
4. Shao CJ, Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol, 2008 , 89: 27-35.
5. 任振义, 金一尊. Ku 蛋白在肿瘤发生中的作用及其靶向抑制策略. 国际放射医学核医学杂志, 2008, 32: 305-307.
6. Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer, 2002, 95: 1199-1205.
7. Tseng RC, Hsieh FJ, Shih CM, et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous endjoining pathway genes: a multiple genotype-phenotype study.Cancer, 2009 , 115: 2939-2948.
8. Kuribayashi T, Ohara M, Sora S, et al. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med, 2010, 25: 25-29.
9. 熊建文, 肖化, 张镇西. MTT 法和CCK-8 法检测细胞活性之测试条件比较. 激光生物学报, 2007, 16: 559 -562.
10. 唐梦琳, 邓万明. 肺癌顺铂耐药的分子机制研究进展. 华西医学, 2009, 24: 238-240 .
11. 方美玉. 进展期非小细胞肺癌治疗进展. 中国呼吸与危重监护杂志, 2008 , 7: 481-484 .
12. 金儿, 任振义, 卢忠, 等. X 线照射后A549 肺癌细胞Ku80 mRNA 及其蛋白表达的变化. 中华放射医学与防护杂志, 2009, 29: 393 -395.
13. Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNAPKcs reveals a large open-ring cradle comprised of HEAT repeats.Nature, 2010, 463 : 118-121.
14. Deriano L, Stracker TH, Baker A, et al. Roles for NBS1 in alternative nonhomologous end-joining of V ( D) J recombination intermediates.Mol Cell, 2009, 34 : 13-25.
15. 韩国栋, 王远东, 袁进, 等. 体外肿瘤药敏试验指导非小细胞肺癌个体户新辅助化疗的临床研究. 内科, 2008 , 3: 493-496 .
16. Xing J, Wu X, Vaporciyan AA, et al. Prognostic significance of ataxia- telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with non-small cell lung cancer.Cancer, 2008 , 112: 2756-2764.
17. Liu B, Wang T, Qian X, et al. Anticancer effect of tetrandrine on primary cancer cells isolated fromascites and pleural fluids. Cancer Lett, 2008, 268: 166-175.

Chinese Journal of Respiratory and Critical Care Medicine

Relationship Between Ku80 Protein Content and Sensitivity to Cisplatin of HumanLung Cancer Cells

Abstract Full text Figures/Tables Video References Cited by

Format

Content